1-10 of 10
Soumya Poddar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jacob Wulff, Rhine Shen, Wangshu Zhang, Soumya Poddar, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2024) 144 (Supplement 1): 864.
https://doi.org/10.1182/blood-2024-194627
Published: 2024
Journal Articles

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Soumya Poddar, Gabriela Balderrama-Gutierrez, Chad M. Williams, Tan Trinh, Subing Cao, Sunanda Kumar, Quinn Walker, Madison Davis, Alessandro Calo, Stacey Valny, Sean C Yoder, Lei Huang, Justin Budka, Jenny J. Kim, Rhine Shen, Simone Filosto, Sophie Viaud, Jorge Andrade, Davide Bedognetti, Mike Mattie
Journal: Blood
Blood (2024) 144 (Supplement 1): 7159.
https://doi.org/10.1182/blood-2024-209570
Published: 2024
Journal Articles

Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Soumya Poddar, Jiali Yan, Gayatri Tiwari, Darawan Rinchai, Wangshu Zhang, Justin Budka, Weixin Peng, Shruti Salunkhe, Madison Davis, Qinghua Song, Sara Beygi, Harry Miao, Mike Mattie, Rhine Shen, Caron A. Jacobson, Davide Bedognetti, Simone Filosto, Sattva S. Neelapu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4368.
https://doi.org/10.1182/blood-2024-211139
Published: 2024
Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Clinical Trials & Observations
Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph Rosenblatt, Ronald Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2024) 143 (6): 496–506.
https://doi.org/10.1182/blood.2023021243
Published: 2024
Includes: Supplemental data
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Caron A. Jacobson, Caroline Falvey, Riemke Bouvier, Sarah Hogan, Elizabeth Kendricken, Julia Jones, Elizabeth Grimm, Robert A. Redd, Eudocia Q Lee, Luis Gonzalez Castro, Ugonma Chukwueke, Jose McFaline Figueroa, Austin I. Kim, Alexandra Torres, Linda Ramsdell, Leslie S. Kean, Ulrike Gerdemann, Alexandre Albanese, Paula Keskula, David Meredith, Lynette Sholl, Soumya Poddar, Madison Davis, Daquin Mao, Simone Filosto, Mike Mattie, Philippe Armand, Lakshmi Nayak
Journal: Blood
Blood (2022) 140 (Supplement 1): 1060–1061.
https://doi.org/10.1182/blood-2022-165256
Published: 2022
Journal Articles

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site

Ulrike Gerdemann, James Kaminski, Alexandre Albanese, Paula Keskula, Lorenzo Cagnin, Kayla Betz, Jillian Zavistaski, Ryan A Fleming, Caroline Falvey, Riemke Bouvier, Julia Jones, Soumya Poddar, Mike Mattie, Ugonma Chukwueke, Alexandra Torres, Caron A. Jacobson, Lakshmi Nayak, Leslie S. Kean
Journal: Blood
Blood (2022) 140 (Supplement 1): 408–409.
https://doi.org/10.1182/blood-2022-166645
Published: 2022
Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jiali Yan, Qinghua Song, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10380–10383.
https://doi.org/10.1182/blood-2022-156120
Published: 2022
Journal Articles

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Ran Reshef, Philip L. McCarthy, Nilanjan Ghosh, Aleksandr Lazaryan, Simone Filosto, Soumya Poddar, Daqin Mao, Andrew Peng, Adrian Kilcoyne, Myrna Nahas, Sattva S. Neelapu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10318–10320.
https://doi.org/10.1182/blood-2022-167688
Published: 2022
Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Clinical Trials & Observations Brief Report
Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, Richard E. Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (12): 1081–1085.
https://doi.org/10.1182/blood.2021010930
Published: 2021
Includes: Supplemental data